We previously reported that PKM2 antagonist (ML265) effectively ameliorated the progression of many chronic liver diseases, including liver fibrosis and NASH (Qu et al., 2024; Zheng et al., 2020). The gene discussed is PKM; the disease is metabolic dysfunction-associated steatohepatitis.